

PORCINE IL-6
LPS
CER001 (20MG)
CER001 (40MG)
pg/ml
2500
2000
1500
1000
500
0
-500
T0
T1
T3
T4
T6
T9
T END
1964.5 ng/ml
1668 ng/ml
1417.43 ng/ml
317 ng/ml
50.81 ng/ml
≈750 ng/ml
775.5 ng/ml
254.117 ng/ml
336.2 ng/ml
≈37 ng/ml
59.2333 ng/ml

FIG. 1



ICAM
LPS
CER001 (20MG)
CER001 (40MG)
ng/mL
25
20
15
10
5
0
0
5
10
15
20
Time (h)

FIG. 3



VCAM
LPS
CER001 (20MG)
CER001 (40MG)
ng/mL
400
300
200
100
0
0
5
10
15
20
Time (h)

FIG. 2



LPS
297.7 ng/ml
86.94 ng/ml
8.48 ng/ml
LPS
CER001 (20MG)
CER001 (40MG)
ng/ml
500
400
300
200
100
0
T0
T1
T3
T4
T6
T9
T END

FIG. 4



Study Schema
RANDOMIZATION 1:1:1:1 (n=20)
GROUP A (n=5)
GROUP B (n=5)
GROUP C (n=5)
GROUP D (n=5)
CONVENTIONAL THERAPY*
CONVENTIONAL THERAPY* + CER-001 5mg/kg BID at day 1,2,3 and 6
CONVENTIONAL THERAPY* + CER-001 10mg/kg BID at day 1,2,3 and 6
CONVENTIONAL THERAPY* + CER-001 20mg/kg BID at day 1,2,3 and 6
*CONVENTIONAL THERAPY: ANTIBIOTIC TREATMENTS AND HEMODYNAMIC SUPPORT ACCORDING TO PATIENT'S CONDITIONS

FIG. 5

Procedure	Baseline	Treatment Period							Follow-up
		Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8
CER-001 Dosing		X	X	X	X	X	X	X	
IL-6	X	X	X	X	X	X	X	X	X
Additional Inflammatory Markers[a]	X								X
Safety Labs[b]	X								X
Concomitant Medication Monitoring	X	X	X	X	X	X	X	X	X
Adverse Event Monitoring	X	--->	--->	--->	--->	--->	--->	--->	X

[a]Includes CRP, D-dimer, Ferritin, IL-8, GM-CSF, MCP 1 and TNF-α
[b]Tested at local hospital lab

FIG. 6

Procedure	Baseline	Treatment Period							Follow-up Day 8
		Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	
CER-001 Dosing		X	X	X	X[d]				
IL-6	X	X	X	X	X	X	X	X	X
Clinical laboratory assessments[a]	X	X	X	X	X	X	X	X	X
Additional Inflammatory Markers[b]	X		X		X		X		X
Safety Labs[c]	X								X
Concomitant Medication Monitoring	X	X	X	X	X	X	X	X	X
Adverse Event Monitoring	X	--->	--->	--->	--->	--->	--->	--->	X

[a] Includes PaO2, PaCO2, P/F Ratio, Modified Borg Dyspnea Scale (MBS), VES, Blood count, LDH, Serum Creatinine, Arterial blood gas test

[b] Includes CRP, D-dimer, Ferritin, IL-8, GM-CSF, MCP 1 and TNF-α

[c] To be tested at local hospital lab

[d] After Day 3, up to two additional doses may be administered at the discretion of the Investigator

FIG. 7